Carvedilol sulfate - Jiangsu HengRui Medicine

Drug Profile

Carvedilol sulfate - Jiangsu HengRui Medicine

Alternative Names: Carvedilol sulfate extended release - Jiangsu HengRui Medicine

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Antioxidants; Beta-adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Heart failure; Hypertension

Most Recent Events

  • 26 Feb 2016 No development reported - Phase-III for Heart failure in China (PO)
  • 26 Feb 2016 No development reported - Phase-III for Hypertension in China (PO)
  • 31 Dec 2013 Phase-III clinical trials in Heart failure in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top